SAIC · Science Applications International Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share non-GAAP | $3.23 | Q1 FY2027 | +0.0% |
|
|
|||
| Adjusted EBITDA non-GAAP | $222M | Q1 FY2027 | +0.0% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP EBITDA 220M
+2M Acquisition, integration, restructuring and impairment costs
-1M Recovery of acquisition, integration, restructuring and impairment costs
+1M Costs related to the settlement of federal tax audits
= Adjusted EBITDA 222M
|
|||
| Adjusted EBITDA as a percentage of revenues non-GAAP | 11.6% | Q1 FY2027 | +0.0% |
|
|
|||
| Adjusted operating income non-GAAP | $221M | Q1 FY2027 | +0.0% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Operating income 179M
+8M Depreciation of property, plant and equipment
+32M Amortization of intangible assets
+2M Acquisition, integration, restructuring and impairment costs
-1M Recovery of acquisition, integration, restructuring and impairment costs
+1M Costs related to the settlement of federal tax audits
= Adjusted operating income 221M
|
|||
| Adjusted operating income as a percentage of revenues non-GAAP | 11.6% | Q1 FY2027 | — |
| Adjusted operating margin non-GAAP | 11.6% | Three Months Ended May 1, 2026 | — |
| Book-to-bill ratio | 1.1 | Q1 FY2027 | — |
|
|
|||
| EBITDA non-GAAP | $220M | Q1 FY2027 | +0.0% |
|
|
|||
| EBITDA as a percentage of revenues non-GAAP | 11.5% | Three Months Ended May 1, 2026 | — |
| Estimated backlog | 22.9B | Q1 FY2027 | — |
| Free cash flow non-GAAP | $118M | Q1 FY2027 | +0.0% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 127M
-9M Expenditures for property, plant, and equipment
+0M Cash used from (provided by) MARPA Facility
= Free cash flow 118M
|
|||
| Funded backlog | 3.7B | Q1 FY2027 | — |
| Negotiated unfunded backlog | $19.12B | May 1, 2026 | — |
| Net bookings | 2.1B | Q1 FY2027 | — |
|
|
|||
| Total backlog | $22.86B | May 1, 2026 | — |
| Trailing twelve months book-to-bill ratio | 1 | Q1 FY2027 | — |
| Adjusted EBITDA Margin % non-GAAP | 10.3% | Q4 FY26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Information Technology Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SAIC
this stock
Science Applications International Corp
|
$5.41B | +27.2% | -2.9% | 14.4 | 5.6% |
|
IBM
International Business Machines Corp
|
$222.04B | -20.4% | +7.6% | 20.9 | 2.4% |
|
ACN
Accenture plc
|
$123.73B | -30.9% | +7.4% | 14.8 | 4.9% |
|
INFY
Infosys Ltd
|
$48.36B | -33.0% | — | — | 3.6% |
|
CTSH
Cognizant Technology Solutions Corp
|
$29.32B | -25.5% | +7.0% | 13.4 | 9.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SAIC | +1.1% | +7.6% | +38.4% | +9.3% | +27.2% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +2.4% | +4.0% | +26.9% | +6.8% | +14.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.